Literature DB >> 1446116

Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy.

A de Roos1, J Doornbos, P R Luyten, L J Oosterwaal, E E van der Wall, J A den Hollander.   

Abstract

Proton-decoupled phosphorus-31 heart spectroscopy was performed in healthy subjects (n = 9) and patients with dilated cardiomyopathy (DCM, n = 9) or hypertrophic cardiomyopathy (HCM, n = 8). The phosphocreatine (PCr)-to-adenosine triphosphate ratio (+/- one standard deviation) after correction for blood contribution and partial saturation was significantly lower in HCM patients relative to the control subjects (1.32 +/- 0.29 vs 1.65 +/- 0.26, P < .05) but not in DCM patients (1.52 +/- 0.58 vs 1.65 +/- 0.26). The inorganic phosphate (Pi) peak was resolved only in patients with the highest spectral quality. Myocardial pH was lower in HCM patients (n = 6) relative to control subjects (n = 4) (7.07 +/- 0.07 vs 7.15 +/- 0.03, P < .05). The Pi/PCr ratio was higher in DCM (n = 3) and HCM (n = 6) patients relative to control subjects (n = 4) (0.29 +/- 0.06 and 0.20 +/- 0.04, respectively, vs 0.14 +/- 0.06; P < .05). Elevated phosphodiester signal in DCM patients correlated with 2,3-diphosphoglycerate signal (r = .94), reflecting blood pool contamination. P-31 spectroscopy enabled detection of abnormalities in cardiac metabolism and determination of pH in patients with HCM and DCM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446116     DOI: 10.1002/jmri.1880020616

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  26 in total

1.  Functional and metabolic consequences of aortic valve replacement.

Authors:  H J Lamb
Journal:  MAGMA       Date:  2000-11       Impact factor: 2.310

Review 2.  Imaging myocardial metabolic remodeling.

Authors:  Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

Review 3.  Cardiac spectroscopy: techniques, indications and clinical results.

Authors:  Meinrad Beer
Journal:  Eur Radiol       Date:  2004-03-06       Impact factor: 5.315

Review 4.  Multi-modality imaging of diastolic function.

Authors:  Michael Salerno
Journal:  J Nucl Cardiol       Date:  2010-04       Impact factor: 5.952

Review 5.  Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Authors:  Valentin Fuster; Sarina van der Zee; Marc A Miller
Journal:  J Cardiovasc Transl Res       Date:  2009-10-16       Impact factor: 4.132

Review 6.  Nonischemic heart failure in diabetes mellitus.

Authors:  Ashrith Guha; Romain Harmancey; Heinrich Taegtmeyer
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

7.  Mitochondrial protein hyperacetylation in the failing heart.

Authors:  Julie L Horton; Ola J Martin; Ling Lai; Nicholas M Riley; Alicia L Richards; Rick B Vega; Teresa C Leone; David J Pagliarini; Deborah M Muoio; Kenneth C Bedi; Kenneth B Margulies; Joshua J Coon; Daniel P Kelly
Journal:  JCI Insight       Date:  2016-02-25

8.  31P-MR spectroscopic imaging in hypertensive heart disease.

Authors:  J-P Heyne; R Rzanny; A Hansch; U Leder; J R Reichenbach; W A Kaiser
Journal:  Eur Radiol       Date:  2006-03-02       Impact factor: 5.315

9.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Quantification of human high-energy phosphate metabolite concentrations at 3 T with partial volume and sensitivity corrections.

Authors:  Abdel-Monem M El-Sharkawy; Refaat E Gabr; Michael Schär; Robert G Weiss; Paul A Bottomley
Journal:  NMR Biomed       Date:  2013-06-03       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.